Introduction: Cerebrovascular disease is the second most common complication in individuals with tumours. The aim of this study was to investigate risk factors, biomarkers, etiology and prognosis of ischemic stroke in cancer patients (ISCPs). Methods: The medical records of 619 consecutive patients who were admitted with acute ischemic stroke from January 2012 to November 2014 were retrospectively evaluated. The patients were divided into two groups (group 1, patients with an active cancer prior to the onset of ischemic stroke; group 2, patients without an active cancer history). The demographic data, risk factors, NIHSS scores, thrombocyte count, D-dimer, fibrinogen and C reactive protein (CRP) level at admission, modified Rankin Scale (mRS) scores in the follow-up period and location of lesions on DWI were recorded. The Mann-Whitney U test, chi-squared test and logistic regression was used for analyzing data, p<0.05 being considered statistically significant. Results: A total of 46 (7.4%) ISCPs were included. Hyperlipidemia was significantly lower in the ISCP group (p=0.001). Elevated thrombocyte counts, D-dimer, fibrinogen and CRP levels at admission, acute multiple ischemic lesions, other causes, mortality in hospital and worse outcome were significantly related to ISCP (p<0.05). On logistic regression analysis, follow up mRS>3, acute multiple ischemic lesions located in more than one vascular territory (AMIMCT) and other causes were significantly associated with ISCP (p<0.001). Conclusion: In our study, other causes, AMIMCT and mRS>3 were more common in the ISCP group. We consider that CCS could be more suitable for detecting other causes than TOAST. Biomarkers could be important in the ISCP group.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980836PMC
http://dx.doi.org/10.22034/APJCP.2018.19.3.649DOI Listing

Publication Analysis

Top Keywords

ischemic stroke
16
risk factors
12
factors biomarkers
8
biomarkers etiology
8
prognosis ischemic
8
stroke cancer
8
cancer patients
8
group patients
8
patients active
8
active cancer
8

Similar Publications

Acute ischemic stroke (AIS) triggers immune responses and neuroinflammation, contributing to brain injury. Histone lactylation, a metabolic stress-related histone modification, plays a critical role in various diseases, but its involvement in cerebral ischemia remains unclear. This study utilized a transient middle cerebral artery occlusion/reperfusion (MCAO/R) model and an oxygen-glucose deprivation/reoxygenation (OGD/R) model to investigate the role of microglial histone lactylation in ischemia-reperfusion injury.

View Article and Find Full Text PDF

Objectives: To investigate the risk factors of recurrence of acute ischemic stroke (AIS) within 1 year and establish a nomogram model for predicting the recurrence risk.

Methods: This study was conducted in two cohorts of AIS patients (≤7 days) hospitalized in Dongzhimen Hospital (modeling set) and Fangshan Hospital (validation set) from March, 2021 to March, 2022. Lasso regression analysis was used to identify the important predictive factors for AIS recurrence within 1 year, and multivariate Logistic regression analysis was performed to analyze the independent factors affecting AIS recurrence.

View Article and Find Full Text PDF

Systematic review and meta-analysis of audits measuring antithrombotic therapy within forty-eight hours for ischemic stroke.

J Stroke Cerebrovasc Dis

December 2024

Stroke and Aging Research Group, Department of Medicine, Monash University, Melbourne, Australia. Electronic address:

Background: Meta-analysis of clinical trials supports the use of early antithrombotic medication in ischemic stroke and transient ischemic attack. It is not known whether this therapy is delivered within the 85% threshold that is acceptable in North America's Get With The Guidelines stroke program.

Aim: to investigate the pooled proportion of patients receiving antiplatelet therapy within 48 hours of ischemic stroke.

View Article and Find Full Text PDF

Development and validation of a rapid point of care CYP2C19 genotyping platform.

J Mol Diagn

December 2024

Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Oxford Road, Manchester, M13 9WL; Division of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester M13 9PT. Electronic address:

Pharmacogenetic guided prescribing can lead to more accurate medicine selection and dosing, improving patient outcomes and leading to better use of healthcare budgets. Loss of function (LoF) variants in CYP2C19 influence an individual's ability to metabolise clopidogrel, increasing the risk of secondary vascular events following ischemic stroke and percutaneous coronary intervention. In acute clinical contexts, centralized laboratory-based testing is too slow to inform timely clinical decision making.

View Article and Find Full Text PDF

Fibrates can prevent and treat ischemic stroke (IS), the occurrence and development of IS is closely related to hypoxia-inducible factor-1A (HIF-1A). However, the exact mechanism by which fibrates regulate HIF-1A to treat IS remains unclear. So network pharmacology and molecular docking were used to explore the mechanism by which fibrates regulate HIF-1A to treat IS, firstly, the structure of five fibrates were obtained by reviewing the literature and pharmacopoeia, then the potential targets of fibrates, IS, HIF1A and HIF1A-related genes were obtained through various databases, their common targets were obtained through Venny 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!